Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 16, Issue 5, 2006, Pages 1794-1800

  Ripley, D ^a   Tunuguntla, R ^a   Susi, L ^a   Chegini, N ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cancer; Menstrual cycle; MMP; Ovary; TIMP

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 26; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CELL TYPE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; EPITHELIUM CELL; FEMALE; GRANULOSA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUTEAL CELL; MENSTRUAL CYCLE; OVARY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TERATOMA; THECA CELL; TISSUE SECTION; TUMOR CELL; VASCULAR ENDOTHELIUM;

AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, SECRETED; MENSTRUAL CYCLE; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 33749125228     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00714.x     Document Type: Article

References (39)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999;49:8-31.
2. Hensley ML. Epithelial ovarian cancer. Curr Treat Options Oncol 2002;3:131-41.
3. Matias-Guiu X, Prat J. Molecular pathology of ovarian carcinomas. Virchows Arch 1998;33:103-11.
4. Kamura T, Jeon JD. Lymph node metastasis in a gynecologic malignancy. Yonsei Med J 2002;43:783-91.
5. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001;11:S37-43.
6. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66.
7. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128-37.
8. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-52.
9. Woessner JF Jr. MMPs and TIMPs - an historical perspective. Mol Biotechnol 2002;22:33-49.
10. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39.
11. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-83.
12. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115(Pt 19):3719-27.
13. Smith MF, Ricke WA, Bakke LJ, Dow MP, Smith GW. Ovarian tissue remodeling: role of matrix metalloproteinases and their inhibitors. Mol Cell Endocrinol 2002;191:45-56.
14. Curry TE Jr, Osteen KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003;24:428-65.
15. Vincent AJ, Salamonsen LA. The role of matrix metalloproteinases and leukocytes in abnormal uterine bleeding associated with progestin-only contraceptives. Hum Reprod 2000;15(Suppl. 3):135-43.
16. Iurlaro M, Loverro G, Vacca A et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest 1999;29:793-801.
17. Moser PL, Hefler L, Tempfer C, Neunteufel W, Kieback DG, Gitsch G. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer. Anticancer Res 1999;19:2365-7.
18. Wu X, Li H, Kang L, Li L, Wang W, Shan B. Activated matrix metalloproteinase-2-a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 2002;84:126-34.
19. Lengyel E, Schmalfeldt B, Konik E et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001;82:291-8.
20. Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol 2001;19:537-42.
21. Schmalfeldt B, Prechtel D, Harting K et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001;7:2396-404.
22. Davidson B, Goldberg I, Berner A et al. Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol 2001;115:517-24.
23. Davidson B, Goldberg I, Gotlieb WH et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17:799-808.
24. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000;17:673-81.
25. Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS, Mok SC. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 2000;77:369-76.
26. Shigemasa K, Tanimoto H, Sakata K et al. Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med Oncol 2000;17:52-8.
27. Tanimoto H, Underwood LJ, Shigemasa K et al. The matrix metalloprotease pump-1 (MMP-7, Matrilysin): a candidate marker/target for ovarian cancer detection and treatment. Tumour Biol 1999;20:88-98.
28. Kikkawa F, Tamakoshi K, Nawa A et al. Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues. Cancer Lett 1997;120:109-15.
29. Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int J Oncol 1998;12:569-76.
30. Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 2001;356:705-18.
31. Park HI, Turk BE, Gerkema FE, Cantley LC, Sang QX. Peptide substrate specificities and protein cleavage sites of human endometase/matrilysin-2/matrix metalloproteinase-26. J Biol Chem 2002;277:35168-75.
32. Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domainorganization required for secretion, latency and activity. J Cancer Res 2000;60:4745-51.
33. de Coignac AB, Elson G, Delneste Y et al. Cloning of MMP-26. A novel matrilysin-like proteinase. Eur J Biochem 2000;267:3323-9.
34. Tunuguntla R, Ripley D, Sang QX, Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 2003;89:453-9.
35. Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE, Sang Q-X.A. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000;275:20540-4.
36. Chegini N, Rhoton-Vlasak A, Williams RS. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Fertil Steril 2003;80:564-70.
37. Furuya M, Ishikura H, Ogawa Y et al. Analyses of matrix metalloproteinases and their inhibitors in cyst fluid of serous ovarian tumors. Pathobiology 2000;68:239-44.
38. Yang TT, Hawkes SP. Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc Natl Acad Sci U S A 1992;89:10676-80.
39. Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998;8:171-7.